SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales.